Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.46 |
| ▸ | PLAU | P00749 | 4/20 | 0.46 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | PLG | P00747 | 3/20 | 0.46 |
| ▸ | PLAT | P00750 | 2/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27999432 | 0.88 | PARP1 (0.50) | — | |
| SCHEMBL31006729 | 0.84 | ALDH1A1 (0.53) | POLBCASR | |
| SCHEMBL17785164 | 0.83 | KMT2A (0.58) | POLB | |
| SCHEMBL17785165 | 0.83 | KMT2A (0.58) | POLB | |
| SCHEMBL14169181 | 0.82 | PRSS1 (0.47) | ITGB3ITGA2BPRSS1PLAUF2 | |
| SCHEMBL4558496 | 0.82 | SMN1; SMN2 (0.44) | ITGB3ITGA2BPRSS1PLAUF2 | |
| SCHEMBL11453058 | 0.81 | PTGS1 (0.55) | — | |
| SCHEMBL11453059 | 0.81 | PTGS1 (0.55) | — | |
| SCHEMBL7146207 | 0.81 | F2 (0.53) | ITGB3ITGA2BPRSS1PLAUF2 | |
| Water SCHEMBL11454954 | 0.80 | PTGS1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4332231-A2 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | Novartis AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| EP-3536776-B1 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230323419-A1 | VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-11512335-B2 | Vertebrate cells and methods for recombinantly expressing a polypeptide of interest | NOVARTIS AG (CH) | 2022-11-29 | — | — | US | disclosed |
| EP-3536776-A1 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | Novartis AG (CH) | 2019-09-11 | — | — | EP | disclosed |
| EP-3137595-B1 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NOVARTIS AG (CH) | 2019-03-13 | — | — | EP | disclosed |
| US-RE46424-E1 | Method for producing 3-amidinophenylalanine derivatives | WILEX AG (DE) | 2017-06-06 | — | — | US | disclosed |
| EP-3137595-A2 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | Novartis AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044587-A1 | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| WO-2015166427-A2 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NOVARTIS AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| US-20110268800-A1 | Unsaturated fatty acids as thrombin inhibitors | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110087025-A1 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7884206-B2 | N-alpha-2,4,6-triisopropylphenylsulfonyl-3-cyano-(L)-phenylalanine-4-ethoxycarbonyl piperazide dissolved in ethanol, mixed with hydroxylamine hydrochloride to produce N- alpha -2,4,6-Triisopropylphenylsulfonyl-3-amidino-(L)-phenylalanine-4-ethoxycarbonyl piperazide hydrochloride, reduction with H2, Pd/C | WILEX AG (DE) | 2011-02-08 | — | — | US | disclosed |
| EP-1957062-A2 | UNSATURATED FATTY ACIDS AS THROMBIN INHIBITORS | LTS LOHMANN Therapie-Systeme AG (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065594-A2 | UNSATURATED FATTY ACIDS AS THROMBIN INHIBITORS | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2007-06-14 | — | — | WO | disclosed |
| US-7211670-B2 | Method for producing 3-amidinophenylalanine derivatives | WILEX AG (DE) | 2007-05-01 | — | — | US | disclosed |
| EP-1098651-B1 | NOVEL UROKINASE INHIBITORS | WILEX AG (DE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1098651-A2 | NOVEL UROKINASE INHIBITORS | Wilex Biotechnology GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004954-A3 | NOVEL UROKINASE INHIBITORS | WILEX BIOTECHNOLOGY GMBH (DE) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000004954-A2 | NOVEL UROKINASE INHIBITORS | WILEX BIOTECHNOLOGY GMBH (DE) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087025-A1 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES | PAH, APEH, DAO | ITGB3 2432/4885ITGA2B 4286/4885PRSS1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.